Business Description
NewAmsterdam Pharma Co NV
NAICS : 325412
SIC : 2834
ISIN : NL00150012L7
Description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5674.17 | |||||
| Equity-to-Asset | 0.83 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 16.43 | |||||
| Beneish M-Score | -1.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -198.4 | |||||
| 3-Year EPS without NRI Growth Rate | -189.1 | |||||
| 3-Year FCF Growth Rate | -167.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.59 | |||||
| 9-Day RSI | 30.56 | |||||
| 14-Day RSI | 36.95 | |||||
| 6-1 Month Momentum % | 121.56 | |||||
| 12-1 Month Momentum % | 72.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.95 | |||||
| Quick Ratio | 6.95 | |||||
| Cash Ratio | 6.82 | |||||
| Days Sales Outstanding | 3111.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1242.76 | |||||
| Net Margin % | -1255.76 | |||||
| FCF Margin % | -1000.76 | |||||
| ROE % | -45.09 | |||||
| ROA % | -39.69 | |||||
| ROIC % | -341.61 | |||||
| ROC (Joel Greenblatt) % | -140777.19 | |||||
| ROCE % | -43.86 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 114.07 | |||||
| PB Ratio | 5.61 | |||||
| Price-to-Tangible-Book | 5.6 | |||||
| EV-to-EBIT | -7.2 | |||||
| EV-to-Forward-EBIT | -7.99 | |||||
| EV-to-EBITDA | -7.2 | |||||
| EV-to-Revenue | 90.37 | |||||
| EV-to-Forward-Revenue | 45.13 | |||||
| EV-to-FCF | -9.23 | |||||
| Price-to-Net-Current-Asset-Value | 5.62 | |||||
| Price-to-Net-Cash | 5.74 | |||||
| Earnings Yield (Greenblatt) % | -13.9 | |||||
| FCF Yield % | -8.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NewAmsterdam Pharma Co NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 12.983 | ||
| EPS (TTM) (€) | -1.978 | ||
| Beta | 0 | ||
| Volatility % | 89.64 | ||
| 14-Day RSI | 36.95 | ||
| 14-Day ATR (€) | 0.46312 | ||
| 20-Day SMA (€) | 19.29 | ||
| 12-1 Month Momentum % | 72.9 | ||
| 52-Week Range (€) | 5.45 - 22 | ||
| Shares Outstanding (Mil) | 89.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NewAmsterdam Pharma Co NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NewAmsterdam Pharma Co NV Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NewAmsterdam Pharma Co NV Frequently Asked Questions
What is NewAmsterdam Pharma Co NV(STU:KH6)'s stock price today?
The current price of STU:KH6 is €17.80. The 52 week high of STU:KH6 is €22.00 and 52 week low is €5.45.
When is next earnings date of NewAmsterdam Pharma Co NV(STU:KH6)?
The next earnings date of NewAmsterdam Pharma Co NV(STU:KH6) is 2024-08-07 Est..
Does NewAmsterdam Pharma Co NV(STU:KH6) pay dividends? If so, how much?
NewAmsterdam Pharma Co NV(STU:KH6) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers